Health Diagnostic Laboratory, Inc. Announces Addition of CYP2C19 Genetic Testing

Jun 23, 2010, 13:56 ET from Health Diagnostic Laboratory, Inc.

RICHMOND, Va., June 23 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. (HDL, Inc.), www.myhdl.com, a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test.  HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.  

"Cytochrome P450 2C19 (CYP2C19) enzyme is involved in the liver's metabolism of several important drugs," said G. Russell Warnick, Chief Scientific Officer at HDL, Inc. and editor of the Handbook of Lipoprotein Testing.   "Most notable of those drugs is Plavix® (clopidogrel) an anti-blood clotting medication.  Clinicians considering Plavix® as a possible preventative therapy for patients should first have their CYP2C19 test results."

The FDA released a safety announcement on March 12, 2010 stating that anywhere from 2-14% of the population are poor metabolizers of Plavix® based on CYP2C19 function.  These patients do not effectively convert Plavix® to its active form because of low CYP2C19 activity reducing the effectiveness of the drug as a preventative therapy for heart attacks, unstable angina, stroke, and cardiovascular death.  

"There is great significance in adding Cytochrome genetic test, as it demonstrates yet another way that advanced testing at HDL, Inc. can help provide better preventative therapy and evidence-based treatments."

HDL, Inc. has made the CYP2C19 test available immediately to all clinicians.  For more information call 1-877-4HDLABS (1-877-443-5227) or visit www.myhdl.com.

About Health Diagnostic Laboratory, Inc.

Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a CAP accredited & CLIA certified clinical laboratory focused on disease state management with supporting clinical laboratory testing targeting patients with cardiovascular disease (CVD), heart failure, stroke, diabetes mellitus (DM), metabolic syndrome (MS), and nonalcoholic steatohepatitis or fatty liver disease (NASH). HDL, Inc. offers a unique menu of clinical laboratory test results, selected based on their ability to discern the information required to understand each patient's disease state.

SOURCE Health Diagnostic Laboratory, Inc.



RELATED LINKS

http://www.myhdl.com